Isoprenaline (hydrochloride)
Isoprenaline (Isoproterenol) hydrochloride is a non-selective, orally active β-adrenergic receptor agonist. Isoprenaline has potent peripheral vasodilator, bronchodilator, and cardiac stimulating activities. Isoprenaline can be used for the research of bradycardia and bronchial asthma[1][2][3][4][5][6].
Product Specifications
CAS Number
51-30-9
Product Name Alternative
Isoproterenol (hydrochloride)
UNSPSC
12352005
Hazard Statement
H315, H319, H335
Target
Adrenergic Receptor; Endogenous Metabolite
Type
Reference compound
Related Pathways
GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling
Applications
COVID-19-immunoregulation
Field of Research
Cardiovascular Disease; Endocrinology
Assay Protocol
https://www.medchemexpress.com/Isoprenaline-hydrochloride.html
Purity
99.86
Solubility
DMSO : 80 mg/mL (ultrasonic) |H2O : ≥ 50 mg/mL
Smiles
OC1=CC=C(C(O)CNC(C)C)C=C1O.Cl
Molecular Formula
C11H18ClNO3
Molecular Weight
247.72
Precautions
H315, H319, H335
References & Citations
M
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture and light)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
β adrenergic receptor
Citation 01
ACS Appl Mater Interfaces. 2023 Apr 12;15 (14) :17518-17531.|ACS Appl Mater Interfaces. 2023 Oct 18;15 (41) :47939-47954.|ACS Nano. 2023 Nov 14;17 (21) :21639-21661.|Acta Pharmacol Sin. 2025 Jun 11.|Biochem Biophys Res Commun. 2022 Feb 12:592:67-73.|Biochem Pharmacol. 2024 May 29:116329.|Biochem Pharmacol. 2025 Aug 8;242 (Pt 1) :117218.|Biochim Biophys Acta Mol Basis Dis. 2024 Mar;1870 (3) :167018.|Biofabrication. 2022 Oct 28;15 (1) .|Biomed Pharmacother. 2021 Jul:139:111562.|Biomed Pharmacother. 2021 Jun:138:111531.|Biomolecules. 2022 Oct 27;12 (11) :1574.|bioRxiv. 2020 Jan.|bioRxiv. 2024 Apr 20.|bioRxiv. 2025 Jul 30.|bioRxiv. 2025 July 11.|Cell Biol Int. 2021 Jan;45 (1) :188-197.|Cell Cycle. 2021 Jul;20 (13) :1253-1269.|Cell Death Differ. 2023 Mar;30 (3) :766-778.|Cell Mol Immunol. 2023 Feb;20 (2) :175-188.|Cell Rep. 2022 Mar 8;38 (10) :110468.|Cell Rep. 2019 Dec 3;29 (10) :2929-2935.e4|Chem Biol Drug Des. 2024 Feb 6.|Chem Eng J. 2024 Sep 1.|Chin Med. 2024 Jun 11;19 (1) :82.|Circulation. 2018 Jun 5;137 (23) :2497-2513.|Curr Issues Mol Biol. 2025 Sep 26;47 (10) :798.|Ecotoxicol Environ Saf. 2025 Nov 15:307:119433.|Emerg Microbes Infect. 2025 Mar 24:2484330.|Eur J Pharmacol. 2020 Nov 5;886:173439.|Eur J Pharmacol. 2021 Sep 15:907:174277.|Eur J Pharmacol. 2024 Oct 30:177085.|FASEB J. 2022 Mar;36 (3) :e22219.|Food Chem Toxicol. 2023 Apr:174:113670.|Food Funct. 2018 Nov 14;9 (11) :5528-5535. |Front Oncol. 2021 Apr 22:11:665763.|Int Immunopharmacol. 2023 Sep 5;124 (Pt A) :110876.|Int J Cardiovasc Imaging. 2025 Jun;41 (6) :1103-1117.|Int J Exp Pathol. 2025 Mar;106 (2) :e12526.|iScience. 2023 Jul 22;26 (9) :107455.|J Adv Res. 2024 Dec 28:S2090-1232 (24) 00624-6.|J Cardiovasc Transl Res. 2023 Aug;16 (4) :758-767.|J Exp Clin Cancer Res. 2019 Apr 25;38 (1) :174. |J Funct Foods. 66 (2020) 1038022.|J Immunother Cancer. 2025 Jun 12;13 (6) :e011611.|J Mol Cell Cardiol Plus. 2024 Dec.|J Pharm Anal. 2024 Jul;14 (7) :100934.|J Tradit Complement Med. 2023 Jul 12;14 (1) :40-54.|J Tradit Complement Med. 2025 Mar 14.|J Transl Med. 2025 Jul 10;23 (1) :762.|Life Sci. 2025 Dec 15:383:124083.|mBio. 2022 Dec 20;13 (6) :e0229722.|Mol Immunol. 2025 Dec:188:45-61.|Molecules. 2024 Feb 7;29 (4) :760.|Nat Commun. 2020 Sep 25;11 (1) :4857.|Nat Prod Commun. 2023, 18 (1) : 1934578X221144581.|Nature. 2025 Dec;648 (8092) :146-156.|Naunyn Schmiedebergs Arch Pharmacol. 2018 Dec;391 (12) :1373-1385. |Naunyn Schmiedebergs Arch Pharmacol. 2025 Mar 17.|Pharmaceuticals (Basel) . 2022 Jan 6;15 (1) :73.|Prostate. 2020 Nov;80 (15) :1328-1340.|Redox Biol. 2024 Dec 21:79:103481.|Res Sq. 2024 Sep 30.|Research Square Preprint. 2021 Jan.|Research Square Preprint. 2023 Sep 14.|Research Square Print. 2023 Feb 7.|Sci Rep. 2024 Jul 8;14 (1) :15683.|Science. 2020 Dec 4;370 (6521) :eaay2002.|SSRN. 2025 May 8.|Toxicol Appl Pharmacol. 2025 Oct:503:117473.|Biomed Res. 2023;44 (3) :105-115.|Inflammation. 2024 Apr;47 (2) :789-806.|J Inflamm Res. 2023 Oct 24:16:4833-4843.|Nutrients. 2023 Mar 9;15 (6) :1340.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
LY400442 100 µg
Aconitase 2 (ACO2) (NM_001098) Human Over-expression Lysate
Sign In for Pricing
View Details 
